1 COVID-19 Outcomes and Genomic characterization of SARS-CoV-2 isolated from 2 **Veterans in New England States** Megan Lee, BS^{1*}; Ya Haddy Sallah, MPH^{1*}; Mary E. Petrone, BS^{2*}; Matthew Ringer, MD³; 3 Danielle Cosentino, BS⁴: Chantal B.F. Vogels, PhD²: Joseph R. Fauver, PhD²: Tara Alpert, 4 PhD²; Nathan D. Grubaugh, PhD²; Shaili Gupta, MBBS^{3,5} 5 ¹Yale School of Medicine, 333 Cedar St., New Haven, CT 06511 6 7 ² Department of Epidemiology of Microbial Diseases, Yale School of Public Health, 60 College 8 St, New Haven, CT 06510 ³ Department of Internal Medicine, Yale School of Medicine, 333 Cedar St, New Haven, CT 9 10 06510 ⁴ Department of Clinical Informatics, AV Connecticut Healthcare System, 950 Campbell Ave, 11 12 West Haven, CT 06516 ⁵Department of Medicine, VA Connecticut Healthcare System, 950 Campbell Ave, West Haven, 13 14 CT 06516 15 *M.L., Y.H.S. and M.E.P. contributed equally to this work and are co-first authors. 16 Running Title: COVID-19 Outcomes and SARS-CoV-2 lineages in New England Veterans 17 18 **Corresponding Author:** 19 Shaili Gupta, MBBS 20 Department of Medicine, Yale School of Medicine 21 VA Connecticut Healthcare System 950 Campbell Ave, Bldg 1, 5th floor, Mailstop 111 22 23 West Haven, CT 06516 E-mail: shaili.gupta@yale.edu; phone: 203-932-5711, ext 4412; fax: 203-932-3748 24

25

Word count: Abstract: 250. Main text: 2,037.

Abstract:

26

- In an older cohort of veterans with a high comorbidity burden, age was the largest predictor of
- hospitalization, peak disease severity, and mortality. Most infections in six New England states
- 29 until September, 2020, were from SARS-CoV-2 B.1 lineage, dominated by spike protein D614G
- 30 substitution in 97.3% of samples.
- 31 **Keywords:** COVID-19, Veterans, Age, SARS-CoV-2, Variant

Background

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

Disease severity and outcomes of Coronavirus Disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) vary among individuals who become infected, with several factors that have been suggested as predictors of mortality, including Charlson comorbidity index score, age, and body mass index (BMI) [2-6]. Virologic characteristics have also been suggested to impact the severity of disease, and concern has been raised about several variants being more transmissible or more lethal [7,8,9,10]. A dynamic nomenclature system (Pangolin) was developed to classify SARS-CoV-2 and identify lineages and mutations that could impact infectivity and virulence [11]. Understanding viral epidemiology and a regional evaluation of viral variants, with their respective clinical correlations, is important to provide a full understanding of the disease. Given the high variability and conflicting data in predicting who will have poor outcomes, assessment of specific populations is necessary to give providers the best clinical picture on their patients. Clinical outcomes of veterans with COVID-19 in New England and respective SARS-CoV-2 genomics have not been described. We aimed to (1) describe patient characteristics, comorbidities, and disease factors that impact patient outcomes and (2) present data on the genomic composition of the SARS-CoV-2 infecting these patients. **Study Design** Our cohort was composed of all veterans receiving care at Veterans Administration (VA) healthcare centers in six New England states (Connecticut, Massachusetts, Maine, New Hampshire, Rhode Island, Vermont) who tested positive for COVID-19 from April 8, 2020, to September 16, 2020. Inclusion criteria included patients with accessible chart records and a

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

diagnosis of COVID-19 based on one of three tests: Xpert[®] Xpress SARS-CoV-2 (Cepheid), Simplexa ® COVID-19 Direct Kit (DiaSorin), and Roche cobas® 6800 system. We manually reviewed charts and recorded demographics [age, gender, race, body-mass index (BMI), longterm care facility (LTC) status, and state of residence when diagnosed with COVID-19]. Comorbidities recorded were immunosuppression, dementia, diabetes mellitus, chronic kidney disease stage ≥ 3, chronic liver disease, coronary artery disease (CAD), heart failure, atrial fibrillation, chronic obstructive pulmonary disease, asthma, and active tobacco use. Clinical database and Viral RNA repositories were created and approved by VA Connecticut Institutional Review Board. Whole genome sequencing was conducted on SARS-CoV-2 isolates with a cycle threshold (Ct) value <36, and provided near-complete or complete genome results where Ct value was <30. We recorded hospitalization status, mortality, and oxygen (O2)-requirement within 24 hours of admission. We divided patients based on their peak disease severity into five categories depending on oxygenation requirements: 1) no O2-requirement, 2) 1-3 liters (L) by nasal cannula (NC), 3) 4-6 L NC, 4) >6 L O2 or non-invasive positive pressure ventilation, and 5) mechanical ventilation. We used STATA v16 for univariate and multivariate logistic regressions to predict the outcomes of interest. We sequenced whole virus genomes ($\geq 20x$ coverage depth across $\geq 70\%$ of the genome) using Illumina (n = 238) and Nanopore (n = 61) platforms. Using BWA-MEM version 0.7.15, we aligned reads to the Wuhan-Hu-1 reference genomes (GenBank MN908937.3). With iVar v1.2.1, we trimmed sequencing adaptors and primer sequences and called bases by simple majority (>50% frequency) at each site to generate consensus genomes. An ambiguous N was used when < 10 reads were present at a site. We aligned consensus genomes with MAFFT [12],

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

and masked problematic sites [13]. We built a phylogenetic tree with IOTree [14] using an HKY substitution model and 1000 bootstraps, visualized it with Python module baltic v0.1.5, and assigned lineages with Pangolin [11]. **Results** Of 476 veterans in six New England states with confirmed SARS-CoV-2 during the study period, 274 had complete and accessible charts. Of 274 veterans, 92.7% were men, 83.2% White, and mean age was 63 years (standard deviation: 17.6 years) and over a third resided in LTC (n=92) (Supplementary Table 1). The most common comorbidities were CAD (27%), diabetes (25%), and tobacco use (23%). Notably, 11.7% patients required O2 above their baseline home O2-requirement within 24 hours of admission, and 20.8% of all patients required O2 support at some point during hospitalization. In terms of peak severity, 78.5% required only room air, 10.9% required 1-3 L O2, 4.0% required 4-6 L O2, 3.6% required >6L O2 or NIPPV, and 2.2% were intubated. The hospitalization rate was 28.8% (Supplementary Figure 1), and overall mortality rate was 10.6% (Supplementary Figure 2). Univariate regression analysis results are reported in Table 1. In multivariate regression, significant predictors of hospitalization were age (OR: 1.05) and non-White race (OR: 2.39) (Table 3). Peak severity also varied by age (OR: 1.07) and O2 requirement on admission (OR: 45.7). Mortality was predicted by age (OR: 1.06), dementia (OR:3.44), and O2 requirement on admission (OR: 6.74). In other words, for every year increase in age, the odds of hospitalization increased by 5%, peak severity increased by 7%, and mortality increased by 6%.

For the genomic characteristics, amongst the 426 patients, 299 patients' genomes had adequate coverage for analysis. We found the majority of our specimens (51.5%) were from SARS-CoV-2 lineage B.1, or a sub-lineage of B.1 (e.g. B.1.302, B.1.303, B.1.356; 137/299, 45.8%), all of which are defined by D614G substitution (Figure 1, Supplementary Table 2). Only 2.4% were from the lineage A that lack the D614G mutation. There were 41 SARS-CoV-2 lineages detected in our cohort, and we did not have the power to test for clinical correlates. Our sequencing data does inform us that the outcomes presented in this VA cohort are dominated by the impacts of the B lineage D614G mutation.

Discussion

Our study found that in an older cohort of veterans with a high comorbidity burden, age significantly associated with risk of hospitalization, peak disease severity, and mortality. The CDC provides a list of chronic medical conditions that predispose individuals to severe illness from SARS-CoV-2 infection [15], but >75% of United States adults fall under a high-risk category [16]. Veterans are a unique cohort because of advanced age on average, and more comorbidities. Understanding clinical factors that impact outcomes in veterans will help clinicians risk-stratify patients with similar demographic profiles.

Many COVID-19 studies have found age to be a predictor of worse outcomes [4,17-20]. In our study, age was a significant predictor for all of our outcomes and was a confounder for other variables. Interestingly, LTC status predicted all three of our outcomes on univariate analysis, but not on multivariate analyses. Earlier in the COVID-19 pandemic, residents of nursing homes had higher rates of infection as well as severe illness and mortality [21]. Our

study shows that among veterans in LTC facility, disease outcomes were not impacted by their residence status.

Concurrent work from our group suggests that O2-requirement within 24 hours of admission predicts poor outcomes in veterans, which has helped inform the triage guidelines at our healthcare system. This is an important finding because other ways of determining oxygenation status can frequently change, and thus become difficult for clinicians to use in practice [22].

Our study supports data from previous reports that non-White patients are at increased risk of hospitalization but have similar peak severity and mortality outcomes [23-26]. Many studies have shown that minorities often have delays in seeking care, causing higher risk of hospitalization when they do seek care [27,28]. This may explain the outcomes in our study. It is critical to continue ongoing efforts to combat medical inequities and target prevention efforts and education to communities and racial groups most affected by COVID-19.

After adjusting for age and other comorbidities, we found that patients with dementia had a higher risk of death. This is similar to other studies on patients with COVID-19 and dementia [18, 29-31]. This may be explained by a host of biological factors, but it emphasizes the importance of extra care and monitoring required when approaching a patient with dementia.

Limitations of this work include the smaller sample size. Furthermore, our study is specific to veterans, which is a largely male and older cohort, and results may not therefore be generalizable. The time period of this study was prior to established medical therapies for COVID-19 and our outcomes reported are likely worse than expected today. Strengths of our study include its comprehensive scope, wide geographic range, manual chart review allowing for

the capturing of all comorbidities and oxygenation parameters that may not be available otherwise in a database, and multivariate analysis of many potential risk factors.

Conclusion

Our study found that in an older cohort of veterans from the six New England states with a high comorbidity burden, age was the single strongest predictor of hospitalization, peak severity, and mortality. Non-white veterans were more likely to be hospitalized, and patients who required oxygen on admission were more likely to have severe disease and higher rates of mortality. Furthermore, patients with dementia were more likely to die. Multiple genomic variants of SARS-CoV-2 were distributed in patients in New England early in the COVID-19 era, mostly from a B.1 sub-lineage with the spike D614G mutation.

Acknowledgements: N.D.G. is a paid consultant of Tempus labs for infectious disease genomics. The other authors report no conflicts of interest. Funding: This work was supported by Centers for Disease Control and Prevention [BAA 75D301-20-R-68024 to N.D.G. and S.G.] and the Yale Center for Clinical Investigation TL1 TR001864 (M.E.P.).

180181 Literature Cited

- U.S. Department of Health & Human Services. Published COVID Data Tracker.
 Accessed May 25, 2021.
- 2. Simonnet A, Chetboun M, Poissy J, et al. High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical Ventilation. *Obesity (Silver Spring)*. 2020;28(7):1195-1199.
- Garg S, Kim L, Whitaker M, et al. Hospitalization Rates and Characteristics of Patients
 Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 COVID-NET, 14
 States, March 1-30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(15):458-464.
- Ioannou GN, Locke E, Green P, et al. Risk Factors for Hospitalization, Mechanical
 Ventilation, or Death Among 10□131 US Veterans With SARS-CoV-2 Infection. *JAMA Netw Open.* 2020;3(9):e2022310.
- 5. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *Jama*. 2020;323(20):2052-2059.
- Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress
 Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan,
 China. JAMA Intern Med. 2020;180(7):934-943.
- 200 7. Brufsky A. Distinct viral clades of SARS-CoV-2: Implications for modeling of viral spread. *Journal of Medical Virology*. 2020;92(9):1386-1390.
- Korber B, Fischer WM, Gnanakaran S, et al. Tracking Changes in SARS-CoV-2 Spike:
 Evidence that D614G Increases Infectivity of the COVID-19 Virus. *Cell*.
 2020;182(4):812-827.e819.
- 205 9. Lorenzo-Redondo R, Nam HH, Roberts SC, et al. A clade of SARS-CoV-2 viruses associated with lower viral loads in patient upper airways. *EBioMedicine*. 2020;62.
- 207 10. Davies NG, Jarvis CI, Edmunds WJ, Jewell NP, Diaz-Ordaz K, Keogh RH. Increased 208 mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. *Nature*. 2021.
- 209 11. Rambaut A, Holmes EC, O'Toole Á, et al. A dynamic nomenclature proposal for SARS-210 CoV-2 lineages to assist genomic epidemiology. *Nature Microbiology*. 2020;5(11):1403-211 1407.
- 12. Katoh K, Standley DM. MAFFT Multiple Sequence Alignment Software Version 7:
 213 Improvements in Performance and Usability. *Molecular Biology and Evolution*.
 214 2013;30(4):772-780.
- Nicola De Maio* CW, Rui Borges, Lukas Weilguny, Greg Slodkowicz, Nick Goldman.
 Masking strategies for SARS-CoV-2 alignments. https://virological.org/t/masking-strategies-for-sars-cov-2-alignments/480. Published 2020. Accessed April 9, 2021.
- Minh BQ, Schmidt HA, Chernomor O, et al. IQ-TREE 2: New Models and Efficient
 Methods for Phylogenetic Inference in the Genomic Era. *Molecular Biology and* Evolution. 2020;37(5):1530-1534.
- 221 15. CDC COVID-19 Guidance for Healthcare Professionals. Underlying Medical Conditions.
 222 Updated May 13, 2021. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html#ref
- 224 16. Ajufo E, Rao S, Navar AM, Pandey A, Ayers CR, Khera A. U.S. population at increased risk of severe illness from COVID-19. *Am J Prev Cardiol*. 2021;6:100156-100156.


- Docherty AB, Harrison EM, Green CA, et al. Features of 20 □ 133 UK patients in hospital
 with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective
 observational cohort study. *BMJ*. 2020;369:m1985-m1985.
- 239 18. Giorgi Rossi P, Marino M, Formisano D, et al. Characteristics and outcomes of a cohort of COVID-19 patients in the Province of Reggio Emilia, Italy. *PLoS One*. 2020;15(8):e0238281-e0238281.
- Kim L, Garg S, O'Halloran A, et al. Risk Factors for Intensive Care Unit Admission and
 In-hospital Mortality among Hospitalized Adults Identified through the U.S. Coronavirus
 Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET). Clin Infect Dis. 2020:ciaa1012.
- 236 20. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. *Nature*. 2020;584(7821):430-436.
- 238 21. Bagchi S MJ, Li Q, et al. *MMWR Morb Mortal Wkly Rep 2021*. Rates of COVID-19 239 Among Residents and Staff Members in Nursing Homes —United States, May 25– 240 November 22, 2020;70:52–55.
- 241 22. Garibaldi BT, Fiksel J, Muschelli J, et al. Patient Trajectories Among Persons
 242 Hospitalized for COVID-19: A Cohort Study. *Ann Intern Med.* 2021;174(1):33-41.
- Cardemil CV, Dahl R, Prill MM, et al. COVID-19-Related Hospitalization Rates and
 Severe Outcomes Among Veterans From 5 Veterans Affairs Medical Centers: Hospital Based Surveillance Study. *JMIR Public Health Surveill*. 2021;7(1):e24502-e24502.
- 24. Gold JAW, Wong KK, Szablewski CM, et al. Characteristics and Clinical Outcomes of
 247 Adult Patients Hospitalized with COVID-19 Georgia, March 2020. MMWR Morb
 248 Mortal Wkly Rep. 2020;69(18):545-550.
- 249 25. Kabarriti R, Brodin NP, Maron MI, et al. Association of Race and Ethnicity With Comorbidities and Survival Among Patients With COVID-19 at an Urban Medical Center in New York. *JAMA network open.* 2020;3(9):e2019795-e2019795.
- 252 26. Azar KMJ, Shen Z, Romanelli RJ, et al. Disparities In Outcomes Among COVID-19
 253 Patients In A Large Health Care System In California. *Health Aff (Millwood)*.
 254 2020;39(7):1253-1262.
- 255 27. Hall WJ, Chapman MV, Lee KM, et al. Implicit Racial/Ethnic Bias Among Health Care
 256 Professionals and Its Influence on Health Care Outcomes: A Systematic Review. Am J
 257 Public Health. 2015;105(12):e60-e76.
- 258 28. Nelson A. Unequal treatment: confronting racial and ethnic disparities in health care. *J Natl Med Assoc.* 2002;94(8):666-668.
- 29. Harrison SL, Fazio-Eynullayeva E, Lane DA, Underhill P, Lip GYH. Comorbidities
 associated with mortality in 31,461 adults with COVID-19 in the United States: A
 federated electronic medical record analysis. *PLoS Med.* 2020;17(9):e1003321-e1003321.
- 30. Miyashita S, Yamada T, Mikami T, Miyashita H, Chopra N, Rizk D. Impact of dementia
 on clinical outcomes in elderly patients with coronavirus 2019 (COVID-19): an
 experience in New York. *Geriatr Gerontol Int.* 2020;20(7):732-734.
- Hariyanto TI, Putri C, Arisa J, Situmeang RFV, Kurniawan A. Dementia and outcomes from coronavirus disease 2019 (COVID-19) pneumonia: A systematic review and meta-analysis. *Arch Gerontol Geriatr.* 2021;93:104299-104299.

Table 1. Univariate and multivariate regression analysis of factors that predict hospitalization, peak severity, and death

	Hospitalization		Peak Severity		Death	
	Unadjusted OR	P-value	Unadjusted OR	P-value	Unadjusted OR	P-value
	(95% CI)		(95% CI)		(95% CI)	
Univariate Regression		-				
Age	1.06 (1.03-1.08)	<0.001*	1.06 (1.04 - 1.09)	<0.001*	1.1 (1.06 - 1.14)	<0.001*
Female Gender	0.41 (0.12- 1.45)	0.17	0.42 (0.95 - 1.9)	0.26	n/a	n/a
Non-White Race	1.97 (1.02 - 3.8)	0.04*	1.3 (0.6 - 2.6)	0.55	0.54 (0.16 - 1.9)	0.33
From Long Term Facility	1.78 (1.04 - 3.07)	0.04*	2.8 (1.5 - 5.1)	0.001*	7.9 (3.2 - 19.2)	<0.001*
BMI < 30	1.52 (0.9 - 2.7)	0.14	1.1 (0.6 - 2)	0.77	5.8 (2.1 - 15.9)	0.001*
Dementia	0.63 (0.29 - 1.4)	0.25	1.6 (0.7 - 3.3)	0.26	7.2 (3.2 - 16.6)	< 0.001*
COPD	3.04 (1.6 - 5.9)	0.001*	1.5 (0.74 - 3.2)	0.25	1.8 (0.7 - 4.5)	0.22
Heart Failure	1.6 (0.7 - 3.5)	0.25	1.8 (0.8 - 4.0)	0.18	1.9 (0.67 - 5.5)	0.23
CAD	2.93 (1.66 - 5.2)	< 0.001*	2.1 (1.2 - 3.9)	0.016*	2.1 (0.9 - 4.6)	0.07
Atrial Fibrillation	2.05 (1.03 - 4.1)	0.04*	3 (1.4 - 5.9)	0.002*	3.1 (1.3 - 7.4)	0.01*
Hospitalization	n/a		n/a		2.58 (1.18-5.65)	0.017*
O2 on admission	n/a		46.2 (19.9, 107.3)	<0.001*	4.34 (1.77 - 10.6)	0.001*
Multivariate Regression						
Age	1.05 (1.03, 1.08)	<.001*	1.07 (1.03 - 1.11)	<0.001*	1.06 (1.01, 1.11)	0.019*
Non-White Race	2.39 (1.13, 5.01)	0.021*				
From long term facility	0.70 (0.36, 1.38)	0.307	1.18 (0.55, 2.55)	0.668	2.0 (0.58, 6.88)	0.273
BMI < 30	n/a		n/a		2.95 (0.81, 10.75)	0.102
Dementia	n/a		n/a		3.44 (1.07, 11.1)	0.038*
COPD	1.73 (0.84, 3.35)	0.136	n/a		n/a	
CAD	1.44 (0.75, 2.81)	0.273	0.71 (0.32, 1.55)	0.390	0.57 (0.209, 1.57)	0.283
Atrial Fibrillation	0.984 (0.45, 2.16)	0.969	1.11 (0.46, 2.64)	0.819	1.25 (0.42, 3.69)	0.686
Hospitalization	n/a		n/a		1.36 (0.40, 4.65)	0.631
O2 on admission	n/a		45.7 (18.79, 111)	<0.001*	6.74 (1.74, 26.1)	0.006*

Abbreviations: BMI – body mass index, CI – confidence interval, CAD – coronary artery disease, CKD – chronic kidney disease, COPD - chronic obstructive pulmonary disease, LTC - long term care, O2 - oxygen, OR - odds ratio, OSA - obstructive sleep apnea

Figure 1. Maximum Likelihood tree of genomes



Supplemental Table 1. Patient Characteristics (n=274)

Table 1 – Patient Characteristics $(n = 274)$					
Demographics		Comorbidities			
Age (years)	62.9+17.6	Immunosuppressed	10 (4)		
Gender		Dementia	42 (15)		
Male	254 (93)	Diabetes	68 (25)		
Female	20 (7)	CKD 3	18 (7)		
Race		Chronic liver disease	32 (12)		
White	228 (83)	Chronic heart disease	107 (39)		
Non-white	46 (17)	CAD	74 (27)		
BMI > 30	110 (40)	Heart failure	29 (11)		
From LTC	92 (34)	Atrial fibrillation	40 (15)		
State		Chronic Lung disease	97 (35)		
Connecticut	89 (32)	COPD	44 (16)		
Massachusetts	150 (55)	Asthma	19 (7)		
Maine	4 (1)	OSA	55 (20)		
New Hampshire	9 (3)	Tobacco Use	62 (23)		
Rhode Island	20 (7)				
Vermont	2(1)				

Results are presented as numbers (percentages).

Abbreviations: LTC - long term care, BMI – body mass index, CKD – chronic kidney disease, CAD – coronary artery disease, COPD – chronic obstructive pulmonary disease, OSA – obstructive sleep apnea

Supplemental Table 2. Lineages of genomes


320

Lineage	Count	Percent
A.1	3	1.0%
A.2	2	0.7%
A.3	2	0.7%
В	1	0.3%
B.1	154	51.5%
B.1.1.10	1	0.3%
B.1.1.113	1	0.3%
B.1.1.128	1	0.3%
B.1.1.163	1	0.3%
B.1.1.192	1	0.3%
B.1.1.225	1	0.3%
B.1.1.307	1	0.3%
B.1.104	4	1.3%
B.1.108	1	0.3%
B.1.110.3	1	0.3%
B.1.2	3	1.0%
B.1.243	1	0.3%
B.1.268	1	0.3%
B.1.280	2	0.7%
B.1.302	26	8.7%
B.1.313	19	6.4%
B.1.319	1	0.3%
B.1.320	1	0.3%
B.1.331	1	0.3%
B.1.356	18	6.0%
B.1.359	8	2.7%
B.1.36	1	0.3%
B.1.369	3	1.0%
B.1.382	1	0.3%
B.1.385	1	0.3%
B.1.390	16	5.4%
B.1.403	1	0.3%
B.1.413	1	0.3%

B.1.448	2	0.7%
B.1.448	1	0.3%
B.1.479	10	3.3%
B.1.509	2	0.7%
B.1.517	1	0.3%
B.1.521	1	0.3%
B.35	1	0.3%
N.1	1	0.3%

Supplemental Figure 1. Percent of patients hospitalized, based on patient demographics and

comorbidities



Supplemental Figure 2. Percent of patients who died, based on patient demographics and

comorbidities

382

